Biomodex develops patient-specific synthetic organs using patented 3D-printing technology that converts medical imaging (CT, echo) into biomechanically accurate organ models with quick turnaround. The company’s core product is used primarily for interventional neuroradiology and is seeing demand from the cardiology space. Led by CEO Thomas Marchand, Biomodex combines 3D printing with proprietary materials and processes to mimic patient-specific tissue behavior. The company intends to expand its product set into interventional cardiology. Biomodex plans to use new funding to develop these cardiology products and to open a new manufacturing facility outside Boston, Massachusetts. The firm is based in Paris, France and Boston, MA.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2018